Executive Director and Head- Early Preclinical Development
Akouos, Inc. (a wholly owned subsidiary of Eli Lilly and Company)
Boston, PA, United States
Michelle D. Valero, PhD is Executive Director, Head of Early Preclinical Development at Eli Lilly and Company. Her current role involves developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with hearing loss. She received a PhD from the University of Texas at San Antonio and has 15 years of research experience in auditory neuroscience. She has presented her work at numerous national and international conferences.
Disclosure information not submitted.
Rationale and Trial Design for an AK-antiVEGF Gene Therapy Trial for Vestibular Schwannoma
Monday, October 13, 2025
9:48 AM - 9:54 AM EDT